Clinical Trial Update: Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC [Phase 3]

View source ↗

Summary

This document describes an ongoing Phase 3 clinical trial evaluating Endostar in combination with an EGFR-TKI for EGFR mutation-positive non-small cell lung can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Endostar (recombinant human endostatin)

Snippet

Sponsor: Zaiwen Fan | Conditions: Advanced Cancer, Lung Cancer, Nonsmall Cell | Phase 3 | Status: UNKNOWN